Author: Prela Cecilia M.
Publisher: Adis International
ISSN: 1170-7690
Source: PharmacoEconomics, Vol.27, Iss.2, 2009-01, pp. : 167-177
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
OOP costs high among Medicare beneficiaries with cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 670, 2013-01 ,pp. :
Olanzapine vs risperidone costs among US Medicaid beneficiaries
Inpharma, Vol. 1, Iss. 1396, 2003-01 ,pp. :
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 428, 2003-01 ,pp. :
Obama to reduce Medicare costs
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 672, 2013-01 ,pp. :
Etanercept or infliximab: costs to US Medicare
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 276, 2000-01 ,pp. :